Literature DB >> 27862275

Long non-coding ribonucleic acid zinc finger antisense 1 promotes the progression of colonic cancer by modulating ZEB1 expression.

Changyi Fang1, Jianbao Zan2, Ben Yue1, Chenchen Liu1, Chenglong He2, Dongwang Yan1.   

Abstract

BACKGROUND AND AIM: Long non-coding RNA zinc finger antisense 1 (ZFAS1) is frequently amplified in hepatocellular carcinoma and promotes metastasis by increasing zinc finger E-box binding homeobox 1 (ZEB1), which can potentiate the progression of epithelial-to-mesenchymal transition (EMT). However, the expression pattern and role of ZFAS1 in colonic cancer remains unknown. The present study aimed to investigate the role of ZFAS1 and its clinical significance in colonic cancer.
METHODS: Paired clinical colonic cancer tissue samples and clinicopathologic characteristics of 73 patients were analyzed. Quantitative real-time polymerase chain reaction analysis was used to evaluate expression levels of ZFAS1 in colonic cancer tissues, cell lines, and plasma. ZEB1 and EMT-related markers expression levels also were explored. Cell biology assays were used to explore the biologic consequences of ZFAS1 in regulating cell proliferation and invasion, as well as the roles in regulating EMT.
RESULTS: Zinc finger antisense 1 was up-regulated in colonic cancer tissues compared with adjacent mucosa (P < 0.01), and its expression level was significantly correlated with TNM stage, vascular invasion, and lymph node metastasis (P < 0.05). ZFAS1 and ZEB1 were also increased in patients' plasma. Moreover, ZFAS1 promoted proliferation, invasion, and impeded apoptosis. Knockdown of ZFAS1 decreased expression of ZEB1 and increased the epithelial markers E-cadherin, ZO-1 while decreasing mesenchymal markers vimentin and N-cadherin.
CONCLUSIONS: Long non-coding RNA ZFAS1 may function as an oncogene by modulating ZEB1 to induce EMT. Manipulation of ZFAS1 level may be a novel approach to suppress colonic cancer progression. In addition, ZFAS1 in plasma has the potential to be a diagnostic biomarker of colonic cancer.
© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  EMT; LncRNA ZFAS1; ZEB1; colonic cancer

Mesh:

Substances:

Year:  2017        PMID: 27862275     DOI: 10.1111/jgh.13646

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  38 in total

1.  Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation.

Authors:  Jin Gao; Yuan Yuan; Lili Zhang; Shaorong Yu; Jianwei Lu; Jifeng Feng; Sainan Hu
Journal:  Cancer Cell Int       Date:  2020-03-23       Impact factor: 5.722

2.  Long non-coding RNA XIST exerts oncogenic functions in human glioma by targeting miR-137.

Authors:  Zong Wang; Jiangwei Yuan; Li Li; Yang Yang; Xuchang Xu; Ying Wang
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 3.  Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

Authors:  Jente van Staalduinen; David Baker; Peter Ten Dijke; Hans van Dam
Journal:  Oncogene       Date:  2018-07-12       Impact factor: 9.867

4.  LncRNA ZFAS1 promotes growth and metastasis by regulating BMI1 and ZEB2 in osteosarcoma.

Authors:  Guangfei Liu; Lu Wang; Hongmin Han; Yong Li; Shouliang Lu; Tiejun Li; Cai Cheng
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

5.  LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis.

Authors:  Yang Ye; Xiaomei Gao; Nanping Yang
Journal:  Hum Cell       Date:  2017-07-18       Impact factor: 4.174

Review 6.  Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside.

Authors:  Long-Yuan Zhou; Si-Nan Lin; Florian Rieder; Min-Hu Chen; Sheng-Hong Zhang; Ren Mao
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

7.  Prognostic role of long noncoding RNA ZFAS1 in cancer patients: a systematic review and meta-analysis.

Authors:  Tian Lan; Xiong Lan; Guangcai Li; Zhen Zheng; Minghua Zhang; Faxiang Qin
Journal:  Oncotarget       Date:  2017-07-11

8.  Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients.

Authors:  Fangteng Liu; Hui Gao; Siyu Li; Xiaolin Ni; Zhengming Zhu
Journal:  Oncotarget       Date:  2017-06-27

Review 9.  Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells.

Authors:  Richard Heery; Stephen P Finn; Sinead Cuffe; Steven G Gray
Journal:  Cancers (Basel)       Date:  2017-04-21       Impact factor: 6.639

Review 10.  Circulating non-coding RNAs as new biomarkers and novel therapeutic targets in colorectal cancer.

Authors:  L Yang; X Zhang; G Hu
Journal:  Clin Transl Oncol       Date:  2021-07-18       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.